Skip to content
Sign in

VCYT · NASDAQ

Veracyte (VCYT) Stock Price & Fundamentals

$479.85+1.53%+$7.24End-of-day price as of Oct 9, 2026

Veracyte (VCYT) closed at $479.85 on Oct 9, 2026, up 1.53% from the previous close of $472.61.

Share price, past year

1Y +1.41%

52-week range $451.02 – $534.40. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$479.85
Sep 30, 2026$463.08
Aug 31, 2026$476.26
Jul 31, 2026$462.88
Jun 30, 2026$464.20
May 29, 2026$492.78
Apr 30, 2026$523.35
Mar 31, 2026$532.88
Feb 27, 2026$512.40
Jan 30, 2026$501.25
Dec 31, 2025$500.48
Nov 28, 2025$478.55
Oct 31, 2025$481.05

Key statistics

Market cap
$38.56B
P/E (TTM)
342.8
EPS (TTM)
$1.40
Revenue (TTM)
$561.90M
Net income (TTM)
$114.48M
Shares outstanding
80.4M
Dividend yield
—
52-week range
$451.02 – $534.40

Veracyte's market cap is $38.56B, based on a share price of $479.85 and 80.4M shares outstanding as of Jun 30, 2026.

Financials

Veracyte reported revenue of $517.15M for fiscal 2025, up 16.01% from fiscal 2024.

Veracyte earned net income of $66.35M in fiscal 2025, a net margin of 12.8%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Veracyte annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$517.15M+16.0%$66.35M12.8%$0.82$126.63M
FY2024ended Dec 31, 2024$445.76M+23.5%$24.14M5.4%$0.31$63.81M
FY2023ended Dec 31, 2023$361.05M+21.8%−$74.40M−20.6%−$1.02$34.26M
FY2022ended Dec 31, 2022$296.54M+35.1%−$36.56M−12.3%−$0.51−$1.01M
FY2021ended Dec 31, 2021$219.51M+86.9%−$75.56M−34.4%−$1.11−$37.00M
FY2020ended Dec 31, 2020$117.48M−2.4%−$34.91M−29.7%−$0.66−$12.55M
FY2019ended Dec 31, 2019$120.37M+30.8%−$12.60M−10.5%−$0.27−$5.99M
FY2018ended Dec 31, 2018$92.01M+27.9%−$23.00M−25.0%−$0.62−$15.40M
FY2017ended Dec 31, 2017$71.95M+10.6%——−$0.91−$25.67M
FY2016ended Dec 31, 2016$65.09M———−$1.09−$32.19M
Veracyte quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$150.32M$25.49M$0.31
Q1 FY2026ended Mar 31, 2026$139.07M$28.71M$0.35
Q4 FY2025ended Dec 31, 2025$140.64M$41.15M$0.50
Q3 FY2025ended Sep 30, 2025$131.87M$19.14M$0.24
Q2 FY2025ended Jun 30, 2025$130.16M−$980.00K−$0.01
Q1 FY2025ended Mar 31, 2025$114.47M$7.05M$0.09
Q4 FY2024ended Dec 31, 2024$118.63M$5.11M$0.07
Q3 FY2024ended Sep 30, 2024$115.86M$15.16M$0.19

Company profile

Name
Veracyte, Inc.
Ticker
VCYT
Exchange
NASDAQ
Industry (SEC SIC)
Services-Medical Laboratories
Headquarters
6000 Shoreline Court, Suite 300, South San Francisco, CA 94080
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001384101

Recent SEC filings

Frequently asked questions

What is Veracyte's stock price?

Veracyte (VCYT) closed at $479.85 on Oct 9, 2026, up 1.53% from the previous close of $472.61.

What is Veracyte's market cap?

Veracyte's market cap is $38.56B, based on a share price of $479.85 and 80.4M shares outstanding as of Jun 30, 2026.

How much revenue does Veracyte make?

Veracyte reported revenue of $517.15M for fiscal 2025, up 16.01% from fiscal 2024.

What is VCYT's P/E ratio?

Veracyte's price-to-earnings ratio is 342.8, based on trailing twelve-month diluted EPS of $1.40.

Does Veracyte pay a dividend?

Veracyte's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Veracyte, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures